Anavex Life Sciences (AVXL) Reports Q3 Loss of $0.06/Share; No Longer Under SEC Investigation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mail
Get Alerts AVXL Hot Sheet
Join SI Premium – FREE
Anavex Life Sciences (NASDAQ: AVXL) reported Q3 EPS of ($0.06), versus ($0.22) reported last year.
The SEC staff recently advised Company’s legal counsel that the staff did not intend to recommend enforcement action by the Commission against the Company in connection with the investigation previously described in the Company’s 2015 Report on Form 10-K.
For earnings history and earnings-related data on Anavex Life Sciences (AVXL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mangoceuticals closes $500K offering at 74% premium to recent price
- Fortune Favor to merge with Quantumsphere in $600M SPAC deal
- Jet fuel prices near $5 per gallon in New York and Los Angeles
Create E-mail Alert Related Categories
Earnings, LitigationRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
